Refers to the presence of cryoglobulins in the serum. Cryoglobulins are immunoglobulins that reversibly precipitate at temperatures below 37°C (below 98.6°F).
Type I cryoglobulinaemia is mostly associated with lymphoproliferative disorders (e.g., Waldenstrom's macroglobulinaemia); types II and III (mixed cryoglobulinaemia) with autoimmune and infectious conditions, particularly with hepatitis C virus (HCV) infection.
Clinical presentation includes a triad of purpura, weakness, and arthralgia. Multi-systemic involvement may include the kidneys, liver, and nervous system.
Diagnosis is based on clinical and laboratory findings. Leukocytoclastic vasculitis is the histological hallmark of mixed cryoglobulinaemia.
Mixed cryoglobulinaemia secondary to chronic HCV infection includes viral eradication strategies in addition to immunosuppression.
Cryoglobulinaemia refers to the presence of cryoglobulins in the serum. Cryoglobulins are immunoglobulins that reversibly precipitate at temperatures below 37°C (below 98.6°F). Type l cryoglobulinaemia is usually associated with lymphoproliferative disorders. Types ll and lll may be associated with infectious (hepatitis C virus infection) or autoimmune disorders.   The clinical presentation includes a triad of purpura, weakness, and arthralgia. Multi-systemic involvement may occur, particularly affecting the kidneys, liver, and nervous system. Widespread small vessel vasculitis has been demonstrated on post-mortem studies.  
Professor of Medicine
Chief, Division of Rheumatology and Clinical Immunology
Medical Director, Musculoskeletal Ultrasound Program
Program Director, Rheumatology Fellowship
University of Florida College of Medicine - Jacksonville
GSK declares that he has no competing interests.
DT has received a fee from an educational grant from the Center of Excellence for organizing CME South Sound Bond Club conference.
University of Turin
AP declares that he has no competing interests.
Instructor in Hematology
Department of Hematology
Hopital Huriez CHRU
XL has received lecture fees and research funding from Janssen-Cilag, Celgene, Chugai, Amgen, Novartis, Mundipharma, and Roche. XL is an author of a number of references cited in this monograph.
Consultant Physician and Rheumatologist
Centre for Rheumatic Diseases
Glasgow Royal Infirmary
RM declares that he has no competing interests.
Use of this content is subject to our disclaimer